Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscan™
NC100150 injection is the code name for an USPIO (ultrasmall superparamagnetic iron oxide) MRI contrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels and on physicochemical properties of the injected contrast medium molecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative characterization of tumor microvasculature and specifically for measures of the microvessel permeability. Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection (Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agents Ferumoxytol from AMAG Pharmaceuticals, Inc. and Vasovist™ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection/Clariscan™ is discontinued.

Phase differences in every second line produce striped ghosts with a shift of half the field of view, so-called Nyquist ghosts.

According to Shannon's sampling theorem, the sampling frequency should be twice the frequency being sampled. The maximum measurable frequency is therefore equal to one half the sampling rate. This is the so-called Nyquist limit. When the frequency is higher than the Nyquist limit, aliasing occurs.

Oversampling is the increase in data to avoid aliasing and wrap around artifacts. Aliasing is the incorrectly mapping of tissue signal from outside the FOV to a location inside the FOV. This is caused by the fact, that the acquired k-space frequency data is not sampled density enough.
Oversampling in frequency direction, done by increasing the sampling frequency, prevents this aliasing artifact. The proper frequency based on the sampling theorem (Shannon sampling theorem/Nyquist sampling theorem) must be at least twice the frequency of each frequency component in the incoming signal. All frequency components above this limit will be aliased to frequencies between zero and half of the sampling frequency and combined with the proper signal information, which creates the artifact. Oversampling creates a larger field of view, more data needs to be stored and processed, but this is for modern MRI systems not a real problem. Oversampling in phase direction (no phase wrap), to eliminate wrap around artifacts, by increasing the number of phase encoding steps, results in longer scan/processing times.

(THK) The thickness of an imaging slice. As the slice profile may not be sharp edged, a criterion such as the distance between the points at half the sensitivity of the maximum (FWHM) or the equivalent rectangular width (the width of a rectangular slice profile with the same maximum height and same area) is used to determine thickness.

For the image quality its important to choose the best fitting slice thickness for an examination. When a small item is entirely contained within the slice thickness with other tissue of differing signal intensity then the resulting signal displayed on the image is a combination of these two intensities. If the slice is the same thickness or thinner than the small structure, only that structures signal intensity is displayed on the image. This partial volume averaging effect explains the vanishing of fine details by choosing slices too large for the scanned object.

See also Partial Volume Artifact.